Loading…
Assembly Biosciences, Inc. is projected to rise to $29.98 by 2027, a +9% move from its current price of $27.40. ASMB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $26.60 | $27.41 | $28.25 | +0.04% |
| Jul 14 | $26.28 | $27.42 | $28.61 | +0.08% |
| Jul 15 | $26.04 | $27.43 | $28.90 | +0.12% |
| Jul 16 | $25.84 | $27.44 | $29.14 | +0.16% |
| Jul 17 | $25.67 | $27.45 | $29.36 | +0.20% |
| Jul 18 | $25.52 | $27.46 | $29.56 | +0.24% |
| Jul 19 | $25.38 | $27.48 | $29.75 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $25.38 | $27.48 | $29.75 | +0.28% |
| Week 2 | $24.62 | $27.55 | $30.83 | +0.55% |
| Week 3 | $24.07 | $27.63 | $31.70 | +0.83% |
| Week 4 | $23.63 | $27.70 | $32.48 | +1.11% |
| Week 5 | $23.26 | $27.78 | $33.18 | +1.39% |
| Week 6 | $22.93 | $27.86 | $33.84 | +1.66% |
| Week 7 | $22.64 | $27.93 | $34.47 | +1.94% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Assembly Biosciences, Inc. is a biotechnology company that develops therapeutic candidates for viral diseases worldwide. It operates in the Healthcare sector and focuses on antiviral programs.
Its pipeline includes long-acting helicase-primase inhibitors ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection; ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses.
The company also has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. It was formerly known as Ventrus Biosciences, Inc.
and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
ASMB is a biotechnology stock operating in healthcare with a current price of $28.90 and a market cap of $572.62M. It holds a rank of 2915 among listed assets. The stock sits at a pivotal level given nearby resistance at $28.90 and a support level at $22.26, with a 30-day trading range of $23.26 to $35.89.
The outlook from the forecast indicates meaningful upside over time, with average prices advancing from the current level toward multi-year highs.
Forecasts show the average price rising to $51.21 by 2030 and to $285.45 by 2050, with max values up to $77.60 by 2030 and as high as $567.99 by 2050. ROI expands from 0% in 2026 to 887.9% by 2050, reflecting a steadily bullish long-range path for ASMB. These figures are estimates and not guarantees, and real results can differ.
A major floor 28.8% below — a decisive break under it would weaken the trend.
The nearest floor, 18.8% below — buyers have tended to step in here.
The nearest ceiling, 5.7% above — a clean break opens room to run.
A major ceiling 20.1% above — clearing it would confirm fresh momentum.
Key ASMB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ASMB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $28.37 | Sell | $27.90 | Sell |
| MA 10 | $27.75 | Sell | $27.49 | Sell |
| MA 20 | $26.00 | Buy | $26.79 | Buy |
| MA 50 | $26.78 | Buy | $26.77 | Buy |
| MA 100 | $27.70 | Sell | $27.36 | Buy |
| MA 200 | $29.19 | Sell | $26.80 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.97 | Neutral |
| Stoch RSI (14) | 50.87 | Neutral |
| CCI (20) | 51.04 | Neutral |
| Williams %R (14) | -33.33 | Info |
| MACD (12,26,9) | 0.33 | Buy |
| ROC (12) | 2.24 | Buy |
| Bollinger %B (20,2) | 0.67 | Neutral |
| Stochastic %K (14) | 66.67 | Neutral |
| TRIX (15) | 0.16 | Buy |
| Awesome (5,34) | 2.58 | Buy |
| Ultimate (7,14,28) | 52.73 | Neutral |
| Momentum (10) | 3.14 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 28.44 | Sell |
| ADX (14) | 17.34 | Neutral |
| ATR (14) | 0.75 | Info |
The 30-day technical picture shows a bullish tilt with RSI(14) at 60, suggesting room for upside after a period of strength. The 50-day simple moving average sits at $26.74, just above the 30-day price action, while the 200-day moving average is at $29.08, indicating a mixed backdrop near longer-term trend lines.
The stock’s price currently sits at $28.90, which aligns with resistance at $28.90 and is above the near-term support of $22.26. The 30-day range spans from $23.26 to $35.89, illustrating a healthy but uneven short-term volatility profile. The overall near-term tone remains constructive given bullish sentiment in the longer horizon and the current technical setup.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $22.26 | $27.40 | $35.35 | 0% | Neutral | |
| $23.65 | $29.98 | $40.35 | +9% | Neutral | |
| $25.06 | $32.78 | $45.92 | +20% | Neutral | |
| $28.37 | $38.07 | $55.02 | +39% | Bullish | |
| $33.20 | $45.59 | $67.64 | +66% | Bullish | |
| $39.03 | $54.71 | $83.06 | +100% | Bullish | |
| $41.65 | $59.53 | $92.24 | +117% | Bullish | |
| $42.88 | $62.42 | $98.53 | +128% | Bullish | |
| $43.75 | $64.82 | $104.07 | +137% | Bullish | |
| $42.95 | $64.69 | $105.53 | +136% | Bullish | |
| $68.93 | $112.05 | $195.24 | +309% | Bullish | |
| $125.79 | $233.52 | $447.74 | +752% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $22.26 | $27.40 | $32.89 | +0.00% |
| August 2026 | $23.21 | $27.47 | $33.43 | +0.24% |
| September 2026 | $23.81 | $28.40 | $34.99 | +3.40% |
| October 2026 | $24.17 | $29.02 | $36.12 | +2.18% |
| November 2026 | $23.40 | $28.25 | $35.47 | -2.64% |
| December 2026 | $23.02 | $27.94 | $35.35 | -1.12% |
Click any year to see its month-by-month ASMB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ASMB to range from $22.26 to $35.35 through 2026. The $27.40 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The ASMB price prediction for 2027 points to an average of $29.98 (low $23.65, high $40.35) — a potential gain of +9% on today's $27.40. A consolidation phase looks the most probable path here.
In 2028, ASMB is projected to trade between $25.06 and $45.92, averaging $32.78 — a potential gain of +20% from today's $27.40. That is up +9% on the projected 2027 average. Price action looks broadly range-bound.
Assembly Biosciences, Inc.'s 2029 outlook centres on $38.07, within a $28.37 to $55.02 range. That is up +16% on the projected 2028 average. That marks a +39% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, ASMB could reach as high as $67.64, with a base case around $45.59 and support toward $33.20 — roughly +66% from $27.40. Momentum favours further upside here.
Expect ASMB to range from $39.03 to $83.06 through 2031. The $54.71 average target implies a +100% move from current prices. That is up +20% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The ASMB price prediction for 2032 points to an average of $59.53 (low $41.65, high $92.24) — a potential gain of +117% on today's $27.40. Momentum favours further upside here.
In 2033, ASMB is projected to trade between $42.88 and $98.53, averaging $62.42 — a potential gain of +128% from today's $27.40. That is up +5% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Assembly Biosciences, Inc.'s 2034 outlook centres on $64.82, within a $43.75 to $104.07 range. That is up +4% on the projected 2033 average. That marks a +137% change versus current levels. Momentum favours further upside here.
By 2035, ASMB could reach as high as $105.53, with a base case around $64.69 and support toward $42.95 — roughly +136% from $27.40. Buyers look set to stay in control over this stretch.
Expect ASMB to range from $68.93 to $195.24 through 2040. The $112.05 average target implies a +309% move from current prices. That is up +73% on the projected 2035 average. Momentum favours further upside here.
The ASMB price prediction for 2050 points to an average of $233.52 (low $125.79, high $447.74) — a potential gain of +752% on today's $27.40. Buyers look set to stay in control over this stretch.
Investing $1,000 in ASMB today (≈ 36.49635 ASMB) could be worth
$8,522.75
+$7,522.75 (+752%) by 2050 · US Dollar
Based on the average projected ASMB price of $233.52 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ASMBwould be worth at today's price.
$1,000 invested in ASMB on Jul 10, 2025 (≈ 54.884744 ASMB) would be worth
$1,503.84
+$503.84 (+50.4%) today · 1.50× · US Dollar
Based on a ASMB entry price of $18.22 vs. today's $27.4.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $27.74 | $987.74 | -1.2% |
| 1 month ago | $22.26 | $1,230.91 | +23.1% |
| 3 months ago | $28.42 | $964.11 | -3.6% |
| 6 months ago | $30.93 | $885.87 | -11.4% |
| 1 year ago | $18.22 | $1,503.84 | +50.4% |
| All time (5.0y) ago | $41.64 | $658.02 | -34.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ASMB forecast.
Our base-case forecast reaches $55.00 around 2032.
Implied market cap at $55.00: $1.09B
The multi-year forecast lays out a path of substantial upside for ASMB. By 2030, the average price is projected at $51.21 with a max of $77.60 and a min of $36.60, delivering a 77.2% ROI. By 2040, the average reaches $131.23 with a max of $235.99 and a min of $77.53, supporting a 354.2% ROI.
By 2050, the average is forecast at $285.45 with a max of $567.99 and a min of $144.72, equating to an 887.9% ROI.
The long-run bullish posture is anchored by a pipeline of Phase 1 candidates across HBV, HDV, and other viral targets, plus a collaboration with Gilead Sciences that could influence development momentum. However, the forecast contends with uncertainty and high volatility, as indicated by the 60% annualized volatility, and the potential for downside moves in the near term given market dynamics. Overall, investors should view these projections as estimates rather than guarantees, recognizing the inherent risk alongside the potential for outsized returns.
Tap a question to reveal the answer.
2030 forecast shows an average price of $51.21 with a min of $36.60 and a max of $77.60, and a 77.2% ROI. The outlook is bullish for 2030.
Forecasts indicate upside with the 2030–2050 average prices rising to $51.21, $131.23, and $285.45 respectively, with ROIs of 77.2%, 354.2%, and 887.9%. These are estimates, not guarantees, and come with notable volatility risk (60% annualized).
Yes. The 2050 forecast shows an average of $285.45, a max of $567.99, and an ROI of 887.9%.
The current price is $28.90 and the market cap is $572.62M.
RSI(14) is 60, SMA(50) is $26.74, SMA(200) is $29.08. The 30-day range is $23.26–$35.89, with support at $22.26 and resistance at $28.90.
Assembly Biosciences, Inc. Community Discussion
0Share your Assembly Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.